Dezhe Pharmaceutical (688192.SH) signed a licensing agreement with AstraZeneca for Shuwozhe, with an initial payment of 600 million USD.

Zhijun Finance and Economics APP News, Dizzycure Pharmaceuticals (688192.SH) announced that the company has signed a License Agreement with AstraZeneca UK Limited (referred to as "AstraZeneca" below), granting AstraZeneca exclusive rights to develop and commercialize Suvorze globally. The company will receive a one-time, non-refundable upfront payment of 600 million US dollars from AstraZeneca, up to 4 billion US dollars in clinical development milestone payments, and up to 5 billion US dollars in sales milestone payments. In addition, the company will receive a stepped royalty rate on Suvorze global sales, ranging from high to low double digits.